Transforming medicine

Unaudited Results for the nine months to 30 September 2018

Further update on FDA regulatory review of BARHEMSYS™ 

Update on FDA regulatory review of BARHEMSYS™

Positive BARHEMSYS™ Phase 3 Treatment Data Published in Anesthesia & Analgesia

Interim Results for the First Half Year 2018

Operating Update for the First Half 2018

$30 Million Credit Facility with Hercules Technology Growth Capital Secured to Support Intended Commercialisation of BARHEMSYS™ in the UK

UK Commercial Operations for BARHEMSYS™ (formerly BAREMSIS®) Expanded Four Key Appointments

BARHEMSYS™ (formerly BAREMSIS®) Prevents Post-Operative Nausea & Vomiting In High-Risk Patients (published in Anesthesiology)

FDA Acceptance Of NDA Filing For BAREMSIS® For The Management Of PONV

Positive Results From 4th And Final Pivotal Phase 3 Trial Of BAREMSIS® For Rescue Treatment Of PONV

Positive Results From Pivotal Phase 3 Trial Of BAREMSIS® For The Treatment Of PONV

Initiation Of Second Pivotal Phase 3 Treatment Trial With BAREMSIS® In PONV

Positive Results From Second Pivotal Phase 3 Prophylaxis Study Of BAREMSIS® In PONV

Dr Patrick Vink To Succeed Ian Kent As Non-Executive Chairman

Positive Results From Phase 2 Study With APD403 In CINV